Phytosterols: Clinical Evidence in Dyslipidaemia and Cardiovascular Health – A Mini Review

Hirjau A.-C.

Published on: 2025-07-02

Abstract

Phytosterols, plant compounds structurally similar to cholesterol, are widely used in functional foods for lipid management. They effectively lower cholesterol by inhibiting intestinal absorption and promoting efflux. Clinical evidence consistently shows that a daily intake of 2 grams reduces LDL-C by approximately 10%, with a favorable safety profile, even in statin-treated patients. Beyond lipid modification, research suggests emerging roles in inflammation, metabolic health, and potentially anticancer effects. While a valuable dietary strategy for dyslipidaemia, large-scale, long-term trials are still needed to definitively establish their direct impact on cardiovascular morbidity and mortality. Some long-term safety aspects, particularly concerning elevated circulating levels and atherosclerosis, also warrant further investigation. Overall, phytosterols demonstrate significant, multifaceted potential in promoting overall cardiometabolic health.

Keywords

Phytosterols; LDL-C; Metabolism; Dyslipidaemia; Physiological roles

Introduction

Plant sterols and plant stanols, collectively termed phytosterols, are naturally occurring compounds structurally analogous to cholesterol, widely distributed in plant-based foods such as vegetable oils, nuts, seeds, and grains [1-4]. Their integration into functional foods has gained considerable traction, primarily owing to their established ability to influence human lipid metabolism [5,6]. Driven by increasing consumer awareness and a robust market growth projected beyond 2030, the need for robust scientific understanding and compelling clinical evidence supporting their health claims has become paramount. This mini-review synthesises contemporary clinical evidence regarding phytosterols' role in dyslipidaemia management and explores their broader impact on cardiovascular health, incorporating recent findings on mechanisms, efficacy, and emerging physiological roles.

Mechanisms of Action of Phytosterols

Phytosterols primarily exert their cholesterol-lowering effect by interfering with the intestinal absorption of both dietary and biliary cholesterol [1,2,7]. Due to their structural similarity, phytosterols effectively compete with cholesterol for incorporation into mixed micelles within the intestinal lumen [1,2,7]. Additionally, specific transporters, such as the Niemann-Pick C1-Like 1 (NPC1L1) protein, are implicated in cholesterol absorption, and phytosterols are thought to compete for binding to this transporter [8,7,9]. Once absorbed into enterocytes, any phytosterols that did cross the membrane were actively effluxed back into the intestinal lumen by ATP-binding cassette (ABC) transporters, specifically ABCG5 and ABCG8, thus minimising their systemic absorption [8,7,9]. This dual mechanism—reduced absorption and enhanced efflux—collectively leads to a decrease in the amount of cholesterol transported from the gut into the bloodstream, consequently lowering circulating low-density lipoprotein cholesterol (LDL-C) levels [1,2,8,7,9].

Evidence for Lipid-Lowering Effects

The LDL-C lowering capacity of phytosterols is well-established across numerous clinical investigations. A foundational consensus panel review by Gylling [10] (2014) affirmed robust LDL-C reductions with phytosterol-enriched foods, noting a consistent absence of significant adverse effects [10]. It has been widely accepted that a daily intake of 2 grams of sterols/stanols typically yields approximately a 10% LDL-C reduction, a finding sustained in longer-term interventions [11]. Recent meta-analyses have confirmed significant reductions in total cholesterol (TC) and LDL-C with phytosterol intake [12]. The benefits of phytosterols extended to specific populations. Plant stanol esters decreased cholesterol in statin-treated type 1 diabetes patients [13], and an "add-on" effect was observed in elderly statin users [14], demonstrating their utility even when patients were already on lipid-lowering medication. Long-term efficacy was further affirmed with significant LDL-C reduction over 12 months in hypercholesterolaemic individuals [15], and plasma phytosterol concentrations were observed to stabilise within four weeks of intake [16].

Beyond Lipid-Lowering: Emerging Health Effects

Whilst their cholesterol-lowering properties remain paramount, an expanding body of research has explored additional, non-lipid-related health effects of phytosterols. Emerging evidence points to roles in inflammation and metabolic health, including potential benefits in non-alcoholic steatohepatitis (NASH) and inflammatory bowel diseases (IBD) [17,18]. Beneficial effects on triglycerides, C-reactive protein (CRP), and blood pressure were also reported [12], and new mechanistic insights suggested influence on glycolipid metabolism by decreasing intestinal glucose absorption [9,17]. Phytosterols may also impact vascular function, with studies suggesting an influence on retinal venular diameter [19]. Research has continued into their anticancer potential, with ongoing studies delving into specific molecular mechanisms [18]. Furthermore, the physiological roles of oxyphytosterols, metabolites formed during processing or storage, are under investigation. Compounds like 7-keto-sitosterol potentially exhibit pro-atherogenic and pro-inflammatory properties, underscoring the complexity of phytosterol metabolism and its broader impact [20].

Current Perspectives and Future Directions

The cumulative clinical evidence consistently demonstrated the efficacy of phytosterols, particularly plant stanols, in significantly reducing LDL-C concentrations. This benefit was observed both as a primary dietary intervention and as an effective add-on strategy in patients receiving statin therapy. Their established safety profile, coupled with reproducible LDL-C lowering, firmly positioned them as a valuable component of dietary strategies for managing dyslipidaemia within a comprehensive cardiovascular risk reduction plan [10]. However, the scientific discourse continues regarding their direct impact on hard cardiovascular outcomes. Whilst extensive evidence supported LDL-C reduction, large-scale, long-term randomised controlled trials with primary endpoints of cardiovascular morbidity and mortality were still needed to definitively establish this direct clinical benefit [10]. This aligned with cautious observations in some recent reviews [14], which also highlighted ongoing questions about long-term safety, particularly concerning observational and genetic studies linking elevated circulating plant sterols with atherosclerosis [14]. The growing understanding of phytosterols roles beyond lipid modification necessitated further rigorous research to elucidate these broader effects, explore optimal dosages for non-lipid targets, and definitively assess their impact on long-term cardiovascular events. Future directions also include the personalisation of phytosterol intake based on genetic predisposition and individual metabolic responses.

Conclusion

In conclusion, phytosterols remain a cornerstone of dietary interventions for dyslipidaemia, consistently demonstrating their ability to reduce LDL-C levels across various patient populations. Whilst their direct impact on hard cardiovascular outcomes requires further investigation through long-term, large-scale trials, emerging research is steadily unveiling their diverse physiological effects beyond lipid modulation. This expanding understanding underscores the multifaceted potential of phytosterols as valuable dietary components in promoting overall health and mitigating cardiometabolic risk.

Author Contributions

A.-C.H. Conceptualization; Formal Analysis; Methodology; Writing-original draft preparation.

Conflicts of Interest: The authors declare no conflicts of interest.

International Journal of Neurobiology